Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

The success of Dupixent has demonstrated ... a more targeted approach to treatment. With its innovative mechanism of action and established success in asthma, Fasenra could address critical ...

The final appraisal document for Dupixent (dupilumab ... aged over 12 with severe asthma characterised by type 2 inflammation and uncontrolled using standard drugs. They also need to be having ...

The ANCHOR studies also met their primary endpoints – treatment with the drug resulted in statistically significant and clinically meaningful reductions in exacerbations (asthma attacks ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...